Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746848 | 1.00 | MEN1 (0.43) | MEN1KMT2AHSP90AA1MAPTALOX15 | |
| SCHEMBL5740305 | 0.97 | MEN1 (0.41) | MEN1KMT2AHSP90AA1MAPTALOX15 | |
| SCHEMBL5743531 | 0.87 | KMT2A (0.36) | MEN1KMT2AHSP90AA1MAPTALOX15 | |
| SCHEMBL1076287 | 0.86 | KMT2A (0.46) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL1077769 | 0.85 | KMT2A (0.43) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL1039157 | 0.84 | LMNA (0.46) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL5789975 | 0.84 | MEN1 (0.46) | MEN1KMT2AHSP90AA1MAPTALOX15 | |
| SCHEMBL27477197 | 0.83 | SMN1; SMN2 (0.43) | MEN1KMT2AMAPTAKR1C3AKR1C2 | |
| SCHEMBL4545983 | 0.83 | MAPT (0.49) | MEN1KMT2AMAPTALOX15AKR1C3 | |
| SCHEMBL2522874 | 0.82 | PDGFRB (0.47) | MEN1KMT2AHSP90AA1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6145298-A | — | — | None | — | — | JP | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024003942-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE | NATCO PHARMA LIMITED (IN) | 2024-01-04 | — | — | WO | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | SHENZHEN TARGETRX, INC. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3176162-B1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-0830136-A4 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIV HAWAII (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-0830136-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996040184-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5348675-A | Biosynthesis, heat resistance | RHONE-POULENC CHIMIE (FR) | 1994-09-20 | — | — | US | disclosed |
| JP-H06145298-A | LIQUID EPOXY RESIN COMPOSITION AND CURED PRODUCT THEREFROM | SHIN ETSU CHEM CO LTD | 1994-05-24 | — | — | JP | disclosed |
| US-5104566-A | Detergents | RHONE-POULENC CHIMIE (FR) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192625-A1 | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME | REN, BRAF, CDK4 | MEN1 1613/4885KMT2A 1435/4885HSP90AA1 3514/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MEN1 1587/4885KMT2A 1258/4885HSP90AA1 3244/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MEN1 3177/4885KMT2A 3839/4885HSP90AA1 3145/4885 |
| US-11066361-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MEN1 3177/4885KMT2A 3839/4885HSP90AA1 3145/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | MEN1 3177/4885KMT2A 3839/4885HSP90AA1 3145/4885 |
| US-20200207709-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | MEN1 3177/4885KMT2A 3839/4885HSP90AA1 3145/4885 |
| US-20030216460-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CCNT1 | MEN1 1679/4885KMT2A 1029/4885HSP90AA1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.